| Customization: | Available |
|---|---|
| CAS No.: | N/a |
| Formula: | C33h57n11o9 |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name |
Lirag |
| CAS NO. | 204656-20-2 |
| Appearance | White freeze-dried powder |
| Purity | 98% HPLC |
| Application | Research peptides |
| Shelf Life | 24 Months |
| Storage | Store at a temperature of 2-8 degrees, protected from light. |
What is Lirag Peptide?
Lirag (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic GLP-1 that stimulates insul.in secretion.
Marketed under the brand name Victoza,Lirag is an injectable developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing Lirag in the U.S. and E.U. under the brand name as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.
Lirag Peptide Benefits
In common to various degrees with other GLP-1 receptor agonists,lirag has advantages over more traditional therapies for type 2 diabetes:
1. Lirag acts in a glucose-dependent manner, meaning Liraglutide will stimulate insul.in secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Lirag has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Lirag decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Lirag lowers blood triglyceride levels.
){kind=link}